Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 5/20 | 0.68 |
| ▸ | ESR2 | Q92731 | 5/20 | 0.68 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | ABHD6 | Q9BV23 | 4/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.40 |
| ▸ | MERTK | Q12866 | 4/20 | 0.40 |
| ▸ | AXL | P30530 | 3/20 | 0.40 |
| ▸ | TYRO3 | Q06418 | 3/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | MMP8 | P22894 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22070855 | 0.89 | ESR1 (0.68) | ESR1ESR2PKMABHD6HDAC8 | |
| SCHEMBL8373032 | 0.83 | ESR1 (0.61) | ESR1ESR2PKMABHD6HDAC8 | |
| SCHEMBL4710037 | 0.82 | ESR1 (0.60) | ESR1ESR2PKMABHD6HDAC8 | |
| SCHEMBL4183920 | 0.81 | ESR1 (0.74) | ESR1ESR2PKMABHD6MERTK | |
| SCHEMBL8266789 | 0.80 | ESR1 (0.72) | ESR1ESR2PKMABHD6HDAC8 | |
| SCHEMBL13259386 | 0.80 | ESR1 (0.72) | ESR1ESR2PKMABHD6HDAC8 | |
| SCHEMBL585650 | 0.80 | ESR1 (0.72) | ESR1ESR2PKMABHD6HDAC8 | |
| SCHEMBL2616863 | 0.80 | ESR1 (0.72) | ESR1ESR2PKMABHD6HDAC8 | |
| SCHEMBL2821470 | 0.80 | ESR1 (0.76) | ESR1ESR2PKMABHD6MERTK | |
| SCHEMBL3865684 | 0.80 | ESR1 (0.72) | ESR1ESR2PKMABHD6MERTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7598243-B2 | inhibit atherosclerotic lesion formation and pathological progression by impairing monocyte recruitment and differentiation in the arterial wall; antiinflammatory, anticarcinogenic agent; autoimmune diseases | MERCK & CO., INC. (US) | 2009-10-06 | — | — | US | disclosed |
| US-20080081803-A1 | Heterocyclic cyclopentyl tetrahydroisoquinoline and tetrahydropyridopyridine modulators of chemokine receptor activity | MERCK SHARP & DOHME CORP. | 2008-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080081803-A1 | Heterocyclic cyclopentyl tetrahydroisoquinoline and tetrahydropyridopyridine modulators of chemokine receptor activity | CCR1, CCR5, CCR2 | ESR1 2066/4885ESR2 692/4885PKM 3618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.